Hessian Labs is transforming cancer diagnostics by moving beyond the limitations of tissue biopsies and DNA mutation–driven models.

Our approach harnesses platelet proteomics — a non-invasive blood test that reflects real-time molecular activity across the body. Platelets selectively capture proteins that drive tumor biology, offering a dynamic readout of cancer onset, growth, and therapeutic response.

At the center of this innovation is ClariaIQ™, our AI-powered informatics platform. ClariaIQ decodes the complex proteomic signatures carried by platelets and translates them into clinically actionable insights. This provides a level of sensitivity, specificity, and temporal resolution unattainable with traditional genomic or tissue-based techniques, enabling earlier detection and more precise patient management